Anlon Healthcare
BSE: AHCL · Pharmaceuticals
Snapshot
Unlock Anlon Healthcare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Anlon Healthcare Limited is a chemical manufacturing company specialising in the production of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company also provides custom manufacturing services for complex and novel chemical compounds.
Business Model
The company generates revenue through the sale of high-purity chemical intermediates and APIs used in finished dosage formulations, nutraceuticals, and veterinary products. It further monetises its technical capabilities by offering custom manufacturing services for specialised chemical compounds.
Growth Outlook
Growth is driven by the recent expansion into custom manufacturing services for complex chemical compounds. The company continues to leverage its expertise in high-purity chemicals to serve diverse sectors including personal care and pharmaceuticals.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality and safety regulations governing the pharmaceutical and chemical manufacturing industries.
- Raw Material Price Volatility. Fluctuations in the cost of chemical raw materials can significantly impact profit margins.
- Market Competition. The pharmaceutical intermediate and API sector is highly competitive, requiring continuous investment in process innovation.
Start your research today
Unlock AI insights, financials, peers and live data on Anlon Healthcare and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Anlon HealthcareAHCL | ₹1,376 Cr | 7.4× | 29.47 | — | 26.6% | 12.5% | 20.1% | -80.8% |
NGL Fine ChemNGLFINE | ₹1,561 Cr | 30.9× | 18.93 | — | 16.8% | 15.8% | 18.4% | +67.7% |
Amrutanjan Health Care LimitedAMRUTANJAN | ₹1,436 Cr | 26.6× | 15.75 | 10.7% | 17.7% | 15.5% | 20.2% | -31.3% |
Jagsonpal Pharmaceuticals LimitedJAGSNPHARM | ₹1,425 Cr | 31.6× | 19.36 | 6.4% | 24.2% | 18.3% | 23.7% | -3.2% |
Bharat Parenterals LimitedBPLPHARMA | ₹1,399 Cr | 53.6× | 20.62 | 10.6% | 19.1% | 7.9% | 8.9% | +58.8% |
Fermenta Biotec.FERMENTA | ₹1,229 Cr | 20.0× | 12.13 | -3.2% | 21.1% | 15.2% | 22.2% | +52.4% |
As of Q2 FY27
Financials
Anlon Healthcare
BSE: AHCL · Pharmaceuticals
Snapshot
Unlock Anlon Healthcare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Anlon Healthcare Limited is a chemical manufacturing company specialising in the production of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company also provides custom manufacturing services for complex and novel chemical compounds.
Business Model
The company generates revenue through the sale of high-purity chemical intermediates and APIs used in finished dosage formulations, nutraceuticals, and veterinary products. It further monetises its technical capabilities by offering custom manufacturing services for specialised chemical compounds.
Growth Outlook
Growth is driven by the recent expansion into custom manufacturing services for complex chemical compounds. The company continues to leverage its expertise in high-purity chemicals to serve diverse sectors including personal care and pharmaceuticals.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality and safety regulations governing the pharmaceutical and chemical manufacturing industries.
- Raw Material Price Volatility. Fluctuations in the cost of chemical raw materials can significantly impact profit margins.
- Market Competition. The pharmaceutical intermediate and API sector is highly competitive, requiring continuous investment in process innovation.
Start your research today
Unlock AI insights, financials, peers and live data on Anlon Healthcare and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Q2 FY27